Presentation of the new M-TRAM program | News from the Department of Medicine

We are delighted to announce the launch of the new Stanford Master of Science in Translational Research and Applied Medicine (M-TRAM) starting in September 2022. This new graduate program will provide formalized training in the sciences of translational medicine, basic sciences to clinical investigation. The program will focus on developing new therapies designed to help patients, including drug therapies, molecular diagnostics, immunotherapies, gene therapies, cell therapies, vaccines and medical devices.

As M-TRAM Director Dean Felsher, MD, PhD, Professor of Oncology and Pathology, explains, “We envisioned an innovative graduate program that will allow anyone, from a recent college graduate to current medicine and/or business (including current students, in-house staff, and fellows) to gain training in emerging methods to realize their dream of contributing to the biomedical innovation revolution through the development of new therapies, diagnostics and technologies.

M-TRAM will fill an unmet need in our community and leverage the world-class basic and translational medical research, bioengineering, and medical technology available at Stanford. The program will combine rigorous didactics with hands-on clinical and laboratory science experiences. The program will consist of 46 total units over 4 terms of core curriculum courses, clinical and research rotations, an industry internship, and a faculty-supervised capstone research project.

The main objective of M-TRAM is to train people for careers in medical translation in universities and industry. The program is open to both internal (Stanford) and external applicants from a variety of backgrounds and experiences, including recent college graduates, medical students, clinical and research fellows, academic research staff, as well as biotech/biopharma professionals. Stanford’s first cohort of internal applicants will begin teaching in fall 2022 and graduate in summer 2023. Subsequent cohorts will include internal and external applicants beginning in fall 2023.

M-TRAM will be led by Felsher and co-directed by Joanna Liliental, PhD, Principal Investigator and Associate Director of the TRAM Program, and George F. Tidmarsh, MD PhD, Adjunct Professor of Pediatrics and Lucille Foundation Board Member Packard for children’s health. Felsher is internationally recognized for his basic and translational medical research in oncology, therapeutics and diagnostics and is the founding director of the TRAM program. Liliental is the founding director of the Translational Applications Service Center (TASC), a Stanford medicine resource center that provides shared access to clinical research technologies, and trains and mentors researchers in translational medicine projects. She is Associate Director of TRAM, a program she established with Felsher, and has mentored and trained more than 500 students, fellows, and faculty. Tidmarsh, who has been involved in the Department of Pediatrics for over 30 years as a professor, has successfully pioneered the development of several therapeutic agents from discovery to full regulatory approval, including DOXIL for the treatment solid tumours, BEXXAR for non-Hodgkin’s lymphoma and GIAPREZA for refractory shock, among others.

To learn more about the Master of Science in Translational Research and Applied Medicine (M-TRAM), please contact Dean Felsher ([email protected]), Joanna Liliental ([email protected]), or George Tidmarsh ([email protected]). edu). And visit the TRAM website []

About Hector Hedgepeth

Check Also

Folbigg’s life and advances in genetic research

New South Wales will conduct a second inquiry into Kathleen Folbigg’s convictions. At the center …